Healthcare Industry News: Calypso 4D
News Release - November 6, 2006
Calypso(R) Medical to Collaborate with IMPAC Medical Systems on Radiation Therapy Solutions for Organ Motion ManagementPHILADELPHIA, Nov. 6 (HSMN NewsFeed) -- Calypso® Medical announces its intention to collaborate on future product offerings with IMPAC Medical Systems, Inc. (IMPAC), an Elekta company. The Calypso® 4D Localization System was designed to provide an objective and continuous method to setup treatment and monitor the patient during radiation delivery without adding ionizing radiation. "Working together with the leaders in the field of radiation therapy we provide the 'missing link' to advance radiation treatment options with continuous target tracking. Today's highly-conformal radiation therapy treatment options rely on knowing the exact location of the target moment to moment. Using proprietary AC electromagnetic technology, the Calypso System provides an unparalleled capability to pinpoint the target continuously throughout the treatment process, without adding ionizing radiation. Our open system architecture design enables the integration of localization and tracking information throughout the care pathway from simulation through treatment delivery. Establishing relationships with companies like IMPAC marks a commitment to advance planning and delivery techniques such as adaptive radiation therapy," notes Eric R. Meier, Calypso Medical's President and CEO. IMPAC intends to integrate target localization data generated from the Calypso® 4D Localization System into its electronic medical record (EMR) which currently streamlines treatment setup, verification, and recording on over 2500 linear accelerators worldwide. "Calypso Medical provides an innovative approach to patient localization. By introducing the technology to IMPAC's large installed base along with new accelerator installations, the potential exists to accelerate the adoption of adaptive therapy," said IMPAC's President and CEO, James Hoey.
About Calypso® Medical
Calypso® Medical Technologies, Inc. ("Calypso") is a Seattle, WA based privately held medical device company. The Company's proprietary tumor localization system utilizes miniaturized implanted devices (Beacon® electromagnetic transponders) to continuously, accurately, and objectively pinpoint the location of tumors for improved accuracy in radiation therapy. Calypso addresses two major issues in modern radiation oncology: errors in treatment set-up and tumor motion during treatment. In addition, the Calypso® 4D Localization System's non-ionizing electromagnetic guidance has the potential to improve work flow efficiency and treatment room utilization. The technology is designed for body-wide cancers commonly treated with radiation therapy, including prostate, breast, lung, head, neck and other radiation therapy target organs. In July 2006, Calypso received 510(k) clearance from the FDA to market the product for use in the prostate only and commercialization commenced Q4 2006. More information can be found at http://www.calypsomedical.com.
About IMPAC Medical Systems, Inc.
IMPAC Medical Systems, Inc., an Elekta company, provides healthcare information technology (IT) solutions that streamline clinical and business operations across the spectrum of cancer care. IMPAC's open integration to multiple healthcare data and imaging systems offers oncology-specific patient charting and practice management, as well as best-of-breed systems for anatomic pathology, clinical laboratory, and cancer registry. With products that are used in association with diagnosis and treatment environments through long-term follow-up, IMPAC provides a comprehensive oncology management solution that helps improve overall communication, process efficiency, and the quality of patient care. For more information about IMPAC products and services, please call 888-GO-IMPAC or visit http://www.impac.com.
Elekta is an international medical-technology Group, providing meaningful clinical solutions, comprehensive information systems and services for improved cancer care and management of brain disorders. All of Elekta's solutions employ non-invasive or minimally invasive techniques and are therefore clinically effective, gentle on the patient and cost-effective.
Clinical solutions include among others Leksell Gamma Knife® for non- invasive treatment of brain disorders and Elekta Synergy® for image guided radiation therapy (IGRT). Following the acquisition of IMPAC Medical Systems Inc. in April 2005, the Elekta Group is the world's largest supplier of oncology software. Elekta's systems and solutions are used at over 4,000 hospitals around the world to treat cancer and manage clinical operations as well as to diagnose and treat brain disorders, including tumors, vascular malformations and functional disorders. With approx. 2,000 employees, Elekta's corporate headquarter is located in Stockholm, Sweden and the company is listed on the Stockholm Stock Exchange under the ticker EKTAb. For more information about Elekta, please visit http://www.elekta.com.
Source: Calypso Medical Technologies
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.